These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 20168201

  • 1. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
    Labarga P, Medrano J, Seclen E, Poveda E, Rodriguez-Novoa S, Morello J, de Mendoza C, Vispo E, Soriano V.
    AIDS; 2010 Mar 13; 24(5):777-9. PubMed ID: 20168201
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE, Chan DJ, Maruszak H, Jeganathan S.
    Int J STD AIDS; 2011 Apr 13; 22(4):228-30. PubMed ID: 21515757
    [Abstract] [Full Text] [Related]

  • 5. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V.
    J Antimicrob Chemother; 2012 Jun 13; 67(6):1475-8. PubMed ID: 22371439
    [Abstract] [Full Text] [Related]

  • 6. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR, Morrow JS.
    Clin Infect Dis; 2008 Oct 01; 47(7):984-5. PubMed ID: 18778234
    [No Abstract] [Full Text] [Related]

  • 7. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.
    Int J Clin Pract; 2011 Dec 01; 65(12):1240-9. PubMed ID: 21999631
    [Abstract] [Full Text] [Related]

  • 8. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
    Podzamczer D, Andrade-Villanueva J, Clotet B, Taylor S, Rockstroh JK, Reiss P, Domingo P, Gellermann HJ, de Rossi L, Cairns V, Soriano V.
    HIV Med; 2011 Jul 01; 12(6):374-82. PubMed ID: 21518220
    [Abstract] [Full Text] [Related]

  • 9. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.
    J Antimicrob Chemother; 2009 Feb 01; 63(2):380-8. PubMed ID: 19036752
    [Abstract] [Full Text] [Related]

  • 10. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.
    Clin Infect Dis; 2009 Nov 15; 49(10):1591-601. PubMed ID: 19842973
    [Abstract] [Full Text] [Related]

  • 11. Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
    TEmAA ANRS 12109 Study GroupINSERM U897, Universite´ Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France. elise.arrive@isped.u-bordeaux2.fr, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Avit D, Kruy LS, McIntyre J, Say L, Gray G, Ekouévi DK, Dabis F.
    AIDS; 2010 Oct 23; 24(16):2481-8. PubMed ID: 20827166
    [Abstract] [Full Text] [Related]

  • 12. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr 28; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract] [Full Text] [Related]

  • 13. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.
    J Antimicrob Chemother; 2009 Dec 28; 64(6):1260-4. PubMed ID: 19776037
    [Abstract] [Full Text] [Related]

  • 14. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.
    Antivir Ther; 2006 Dec 28; 11(2):233-43. PubMed ID: 16640104
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
    Si-Ahmed SN, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, Deterding K, Dumortier J, Bailly F, Esteban R, Wedemeyer H, Janssen HL, Zoulim F.
    Antiviral Res; 2011 Oct 28; 92(1):90-5. PubMed ID: 21767570
    [Abstract] [Full Text] [Related]

  • 16. Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.
    Amoroso A, Gilliam BL, Talwani R, Boyce C, Redfield RR, Davis CE.
    HIV Clin Trials; 2009 Oct 28; 10(5):320-3. PubMed ID: 19906624
    [Abstract] [Full Text] [Related]

  • 17. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
    De Clercq E.
    Expert Opin Pharmacother; 2009 Dec 28; 10(17):2935-7. PubMed ID: 19929712
    [Abstract] [Full Text] [Related]

  • 18. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
    Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M, ARCA Collaborative Group.
    AIDS; 2010 Apr 24; 24(7):1013-8. PubMed ID: 20124969
    [Abstract] [Full Text] [Related]

  • 19. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
    Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ.
    AIDS; 2011 May 15; 25(8):1051-6. PubMed ID: 21346511
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
    Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW, Swiss HIV Cohort study, HAART Observational Medical Evaluation and Research Cohort, Netherlands ATHENA Observational Cohort.
    Antivir Ther; 2009 May 15; 14(7):931-8. PubMed ID: 19918097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.